newsfilter
← Latest News
ACCESS Newswire·

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Tulmimetostat follows pelabresib and tafasitamab as the company's third clinical program to receive Fast Track designationPLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG